Focal nodular hyperplasia, hepatocellular adenomas: Past, present, future;Hyperplasie nodulaire focale, adénomes hépatocellulaires: Passé, présent, futur

Gastroenterologie Clinique et Biologique

Volumn 34, Issue 6-7, 2010, Pages 355-358

  Bioulac Sage, P ^a,b   Balabaud, C ^b,c   Zucman Rossi, J ^d  

^a HÔPITAL PELLEGRIN   (France)

^b INSERM   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d Université Paris 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CARBAMAZEPINE; DANAZOL; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; VALPROIC ACID;

ANEMIA; DIABETES MELLITUS; DISEASE CLASSIFICATION; FATTY LIVER; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER FOCAL NODULAR HYPERPLASIA; MALIGNANT TRANSFORMATION; NEPHROTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; SHORT SURVEY; TELANGIECTASIA;

ADENOMA, LIVER CELL; FOCAL NODULAR HYPERPLASIA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; MUTATION; RISK FACTORS; TERMINOLOGY AS TOPIC;

EID: 77955414765     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2010.03.014     Document Type: Short Survey

References (31)

1. Edmondson HA. Tumors of the liver and intrahepatic bile ducts. Atlas of tumor pathology, VII, 25 (Armed forces Institute of pathology);1958.
2. Bluteau O., Jeannot E., Bioulac-Sage P., Marqués J.M., Blanc J.F., Bui H., et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002, 32:312-315.
3. Chen Y.W., Jeng Y.M., Yeh S.H., Chen P.J. P53 gene and Wnt signaling in benign neoplasms: β-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 2002, 36:927-935.
4. Zucman-Rossi J., Jeannot E., Nhieu J.T., Scoazec J.Y., Guettier C., Rebouissou S., et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006, 43:515-524.
5. Bioulac-Sage P., Rebouissou S., Thomas C., Blanc J.F., Sa Cunha A., Rullier A., et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007, 46:740-748.
6. Rebouissou S., Amessou M., Couchy G., Poussin K., Imbeaud S., Pilati C., et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009, 457:200-204.
7. Laumonier H., Bioulac-Sage P., Laurent C., Zucman-Rossi J., Balabaud C., Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 2008, 48:808-818.
8. Sa Cunha A., Blanc J.F., Lazaro E., Mellottee L., Le Bail B., Zucman-Rossi J., et al. Inflammatory syndrome with liver adenomatosis: the beneficial effects of surgical management. Gut 2007, 56:307-309.
9. Bacq Y., Jacquemin E., Balabaud C., Jeannot E., Scotto B., Branchereau S., et al. Familial liver adenomatosis associated with hepatocyte nuclear factor-1 alpha inactivation. Gastroenterology 2003, 125:1470-1475.
10. Reznik Y., Dao T., Coutant R., Chiche L., Jeannot E., Clauin S., et al. Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab 2004, 89:1476-1480.
11. Paradis V., Laurent A., Flejou J.F., Vidaud M., Bedossa P. Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation. Hepatology 1997, 26:891-895.
12. Rebouissou S., Bioulac-Sage P., Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol 2008, 48:163-170.
13. Paradis V., Bièche I., Dargère D., Laurendeau I., Nectoux J., Degott C., et al. A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia. Gastroenterology 2003, 124:651-659.
14. Rebouissou S., Couchy G., Libbrecht L., Balabaud C., Imbeaud S., Auffray C., et al. The β-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. J Hepatol 2008, 49:61-71.
15. Bioulac-Sage P., Laumonier H., Rullier A., Cubel G., Laurent C., Zucman-Rossi J., et al. Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int 2009, 29:459-465.
16. Baum J.K., Bookstein J.J., Holtz F., Klein E.W. Possible association between benign hepatomas and oral contraceptives. Lancet 1973, 2:926-929.
17. Bioulac-Sage P., Laumonier H., Couchy G., Le Bail B., Sa Cunha A., Rullier A., et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009, 5:481-489.
18. Dokmak S., Paradis V., Vilgrain V., Sauvanet A., Farges O., Valla D., et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009, 137:1698-1705.
19. Foster J.H., Donohue T.A., Berman M.M. Familial liver-cell adenomas and diabetes mellitus. N Engl J Med 1978, 299:239-241.
20. Paradis V., Champault A., Ronot M., Deschamps L., Valla D.C., Vidaud D., et al. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology 2007, 46:140-146.
21. Jeannot E, Mellottee L, Bioulac-Sage P, Balabaud C, Scoazec JY, Tran Van Nhieu, et al. Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in MODY3 patients and suggests genotoxic damage. Diabetes 2010, 14 (online).
22. Foster J.H., Berman M.M. The malignant transformation of liver cell adenomas. Arch Surg 1994, 129:712-717.
23. Flejou J.F., Barge J., Menu Y., Degott C., Bismuth H., Potet F., et al. Liver adenomatosis. An entity distinct from liver adenoma?. Gastroenterology 1985, 89:1132-1138.
24. Wanless I.R., Albrecht S., Bilbao J., Frei J.V., Heathcote E.J., Roberts E.A., et al. Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: a new syndrome. Mod Pathol 1989, 2:456-462.
25. Bioulac-Sage P., Rebouissou S., Sa Cunha A., Jeannot E., Lepreux S., Blanc J.F., et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 2005, 128:1211-1218.
26. Bioulac-Sage P, Balabaud C, Zucman-Rossi J. What's in a name? Hepatology 2010;51:1086-7.
27. Terminology of nodular hepatocellular lesions. International working party. Hepatology 1995;22:983-93.
28. Rebouissou S., Imbeaud S., Balabaud C., Boulanger V., Bertrand-Michel J., Terce F., et al. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element binding protein (ChREBP) activation. J Biol Chem 2007, 282:14437-14446.
29. Pelletier L., Rebouissou S., Paris A., Rathahao-Paris E., Perdu E., Bioulac-Sage P., et al. Loss of hepatocyte nuclear factor-1 alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology 2010, 51:557-566.
30. Terkivatan T., Ijzermans J.N. Hepatocellular adenoma: should phenotypic classification direct management?. Nat Rev Gastroenterol Hepatol 2009, 6:697-698.
31. Bosman FT, Carneiro F, Hruban RH, Theise ND. " World Health Organization (WHO) Classification of Tumours of the Digestive System" , 4th ed; 2010 (in press).